How has been the historical performance of Vanta Bioscience?

Answer:The historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this decline, falling to -7.56 in March 2025 from -3.68 in March 2024. On the balance sheet, total liabilities increased to 85.88 Cr in March 2025, up from 85.40 Cr in March 2024, while total assets also rose to 85.88 Cr. The cash flow from operating activities turned negative at -2.00 Cr in March 2025, compared to a positive 2.00 Cr in March 2024. Breakdown: Vanta Bioscience's financial performance has been characterized by a significant decline in net sales, which fell to 1.96 Cr in March 2025 from 9.72 Cr in the previous year. This decline in revenue has been accompanied by a sharp increase in total expenditure, resulting in an operating loss of -4.15 Cr in March 2025. The company's profitability metrics, including profit before tax and profit after tax, have also deteriorated, with figures of -4.11 Cr and -4.77 Cr respectively for March 2025. The earnings per share have similarly dropped to -7.56. On the balance sheet, total liabilities increased slightly to 85.88 Cr, while total assets matched this figure, indicating a challenging financial position. The cash flow from operating activities has turned negative, reflecting ongoing operational difficulties. Overall, Vanta Bioscience's financial trajectory suggests significant challenges in maintaining revenue and profitability over the recent years.